Briacell Therapeutics Corp
BCTX8.950USD
-0.060-0.67%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
16.86MMarket Cap
LossP/E TTM
More Details of Briacell Therapeutics Corp Company
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. Bria-IMT, its Phase 3 lead candidate, is a patented, off-the-shelf, cell-based, targeted immunotherapy that activates the patient’s immune system to specifically kill cancer cells without harming other cells. The Company is advancing its Bria-IMT targeted immunotherapy in combination with an immune check point inhibitor (Retifanlimab) in a pivotal Phase 3 study in metastatic breast cancer. It is also developing personalized off-the-shelf immunotherapies, Bria-OTS and Bria-OTS+, which provides a platform technology to develop personalized off-the-shelf immunotherapies for numerous types of cancer, and a soluble CD80 protein therapeutic which act both as a stimulator of the immune system, as well as an immune checkpoint inhibitor. Its pipeline also includes Bria-IMT + CPI, Bria-BRES/BRES+, Bria-PROS+, Bria-LUNG+ and Bria-MEL+.
Briacell Therapeutics Corp Info
Ticker SymbolBCTX
Company nameBriacell Therapeutics Corp
IPO dateOct 12, 2006
CEOWilliams (William V)
Number of employees22
Security typeOrdinary Share
Fiscal year-endOct 12
AddressSuite 300 - Bellevue Centre, 235 -15th Street
CityWEST VANCOUVER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryCanada
Postal codeV7T 2X1
Phone16049211810
Websitehttps://briacell.com/
Ticker SymbolBCTX
IPO dateOct 12, 2006
CEOWilliams (William V)
Company Executives of Briacell Therapeutics Corp
Name
Name/Position
Position
Shareholding
Change
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.13K
-96.81%
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
799.00
-25.81%
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
163.00
+36.97%
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
18.00
-99.81%
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
-100.00%
Dr. Giuseppe Del Priore, M.D.
Dr. Giuseppe Del Priore, M.D.
Chief Medical Officer
Chief Medical Officer
--
-100.00%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
--
-100.00%
Dr. Miguel A. Lopez-Lago
Dr. Miguel A. Lopez-Lago
Chief Scientific Officer
Chief Scientific Officer
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Dr. William V. Williams, M.D.
Dr. William V. Williams, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.13K
-96.81%
Mr. Jamieson Bondarenko
Mr. Jamieson Bondarenko
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
799.00
-25.81%
Mr. Vaughn C. Embro-pantalony, CPA
Mr. Vaughn C. Embro-pantalony, CPA
Independent Director
Independent Director
163.00
+36.97%
Mr. Gadi Levin
Mr. Gadi Levin
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
18.00
-99.81%
Mr. Martin E. Schmieg, CPA
Mr. Martin E. Schmieg, CPA
Independent Director
Independent Director
--
--
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Independent Director
Independent Director
--
-100.00%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Iroquois Capital Management, LLC
3.04%
L5 Capital Inc.
0.92%
Citadel Advisors LLC
0.59%
Lynwood Capital Management Inc.
0.57%
3I Management LLC
0.49%
Other
94.40%
Shareholders
Shareholders
Proportion
Iroquois Capital Management, LLC
3.04%
L5 Capital Inc.
0.92%
Citadel Advisors LLC
0.59%
Lynwood Capital Management Inc.
0.57%
3I Management LLC
0.49%
Other
94.40%
Shareholder Types
Shareholders
Proportion
Hedge Fund
3.62%
Investment Advisor/Hedge Fund
1.05%
Corporation
0.92%
Individual Investor
0.20%
Research Firm
0.07%
Other
94.13%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
56
89.53K
11.56%
--
2025Q3
57
89.53K
11.57%
-92.49K
2025Q2
57
26.02K
16.36%
-45.38K
2025Q1
52
22.47K
15.34%
-34.43K
2024Q4
50
15.20K
6.22%
+1.50K
2024Q3
50
13.69K
8.50%
+382.00
2024Q2
50
13.31K
14.82%
-1.36K
2024Q1
50
14.67K
20.08%
-6.72K
2023Q4
54
16.54K
21.77%
-1.66K
2023Q3
61
18.44K
35.51%
-444.00
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Iroquois Capital Management, LLC
56.00K
2.97%
+56.00K
--
Jul 21, 2025
L5 Capital Inc.
17.40K
0.92%
+450.00
+2.65%
Dec 10, 2024
Lynwood Capital Management Inc.
10.65K
0.57%
+114.00
+1.08%
Mar 31, 2024
3I Management LLC
9.17K
0.49%
-27.73K
-75.15%
Mar 31, 2025
Williams (William V)
35.30K
1.87%
+28.26K
+401.29%
Aug 01, 2025
Desjardins Securities Inc.
350.00
0.02%
+350.00
--
Jun 30, 2025
Bondarenko (Jamieson)
1.08K
0.06%
+278.00
+34.79%
Dec 09, 2024
Embro-Pantalony (Vaughn C)
119.00
0.01%
+22.00
+22.68%
Dec 09, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 05, 2025
Merger
10→1
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Date
Type
Ratio
Aug 05, 2025
Merger
10→1
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
Jan 03, 2025
Merger
15→1
FAQs
Who are the top five shareholders of Briacell Therapeutics Corp?
The top five shareholders of Briacell Therapeutics Corp are:
Iroquois Capital Management, LLC holds 56.00K shares, accounting for 2.97% of the total shares.
L5 Capital Inc. holds 17.40K shares, accounting for 0.92% of the total shares.
Lynwood Capital Management Inc. holds 10.65K shares, accounting for 0.57% of the total shares.
3I Management LLC holds 9.17K shares, accounting for 0.49% of the total shares.
Williams (William V) holds 35.30K shares, accounting for 1.87% of the total shares.
Iroquois Capital Management, LLC holds 56.00K shares, accounting for 2.97% of the total shares.
L5 Capital Inc. holds 17.40K shares, accounting for 0.92% of the total shares.
Lynwood Capital Management Inc. holds 10.65K shares, accounting for 0.57% of the total shares.
3I Management LLC holds 9.17K shares, accounting for 0.49% of the total shares.
Williams (William V) holds 35.30K shares, accounting for 1.87% of the total shares.
What are the top three shareholder types of Briacell Therapeutics Corp?
The top three shareholder types of Briacell Therapeutics Corp are:
Iroquois Capital Management, LLC
L5 Capital Inc.
Citadel Advisors LLC
Iroquois Capital Management, LLC
L5 Capital Inc.
Citadel Advisors LLC
How many institutions hold shares of Briacell Therapeutics Corp (BCTX)?
As of 2025Q4, 56 institutions hold shares of Briacell Therapeutics Corp, with a combined market value of approximately 89.53K, accounting for 11.56% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.01%.
What is the biggest source of revenue for Briacell Therapeutics Corp?
In --, the -- business generated the highest revenue for Briacell Therapeutics Corp, amounting to -- and accounting for --% of total revenue.
